[Histonet] IHC Patient Negatives

[Karin Groeger]

I totally agree with you.

Karin Groeger

Histology Supervisor

US LABS, Irvine,CA

949-450-0145 ext. 649


-----Original Message-----
From: histonet-bounces <@t> lists.utsouthwestern.edu [mailto:histonet-bounces <@t> lists.utsouthwestern.edu] On Behalf Of Martha Ward
Sent: Wednesday, October 28, 2009 12:21 PM
To: Patti Loykasek; Josie Britton; histonet <@t> lists.utsouthwestern.edu
Subject: RE: [Histonet] IHC Patient Negatives

Patti,

I agree with you.  We do not run another negative control under the circumstances you and Josie outlined.

Martha Ward, MT (ASCP) QIHC
Assistant Manager, Molecular Diagnostics Lab
Wake Forest University Baptist Medical Center
 

-----Original Message-----
From: histonet-bounces <@t> lists.utsouthwestern.edu [mailto:histonet-bounces <@t> lists.utsouthwestern.edu] On Behalf Of Patti Loykasek
Sent: Wednesday, October 28, 2009 2:57 PM
To: Josie Britton; histonet <@t> lists.utsouthwestern.edu
Subject: Re: [Histonet] IHC Patient Negatives

Well, I hope I don¹t start a controversy, but here's my 2 cents worth. I don't think you should run another negative. If you are going to have any staining due to intrinsic tissue elements reacting with your detection, you will see it the first day. I am of the opinion that in most cases too many negative controls are run. You are wasting precious patient material. With today's polymer detection systems, there is very little background staining.
If you are doing additional testing on a patient using a different type of detection, I do think you should run another negative.

Please don't flame me too badly - I'm having a bad day! And it is only my 2 cents worth!


Patti Loykasek BS, HTL, QIHC
Clinical Lab Supervisor
PhenoPath Laboratories
Seattle, WA






> Hi All,
> 
> 
> 
> I have an issue with my computer, so I cannot see past the little 
> paragraphs on the Histonet archives.  Sorry!  This question is 
> probably asked many, many times.
> 
> 
> 
> When we run our IHC's we always have a patient negative slide to go 
> with our case.  We run everything accept Herceptin on the Bond. When 
> running a patient's IHC on the bench and on the Bond we use a negative 
> patient control for both.  (We run a test control on all antibodies 
> also)  If we are running a double stain IHC also we run another 
> negative patient control for that stain also.  The debate we are 
> having is, if the next day you run another IHC on the same patient 
> using the same DAB define kit, should we be running another negative patient control?
> 
> 
> 
> Thanks for your help!
> 
> 
> 
> Josie Britton HT
> 
> Cheshire Medical Center
> 
> 
> 
> 
> CONFIDENTIALITY NOTICE: This electronic message, including any 
> attachments, is for the sole use of the intended recipients and may 
> contain confidential and privileged information.  Any unauthorized 
> review, use, disclosure or distribution is prohibited.  If you are not 
> the intended recipient, please contact the sender by electronic mail 
> and destroy all copies of the original message.
> _______________________________________________
> Histonet mailing list
> Histonet <@t> lists.utsouthwestern.edu
> http://lists.utsouthwestern.edu/mailman/listinfo/histonet
> 



This e-mail message, including any attachments, is for the sole use of the intended recipients and may contain privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by e-mail and destroy all copies of the original message, or you may call PhenoPath Laboratories, Seattle, WA U.S.A. 
at (206) 374-9000.


_______________________________________________
Histonet mailing list
Histonet <@t> lists.utsouthwestern.edu
http://lists.utsouthwestern.edu/mailman/listinfo/histonet

_______________________________________________
Histonet mailing list
Histonet <@t> lists.utsouthwestern.edu
http://lists.utsouthwestern.edu/mailman/listinfo/histonet



Confidentiality Notice: This message, including any attachments, may contain CONFIDENTIAL AND/OR LEGALLY PRIVILEGED information. The information is intended for use by the individual named above and may not be disseminated to any other party without US LABS' written permission. If you are not the intended recipient, or the employee or agent responsible for delivering this information to the intended recipient, you are hereby notified that any dissemination, disclosure, distribution, copying or taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this information in error, please notify US LABS immediately at 1-888-450-0145 attn: Compliance Department to arrange for return of this message including all attachments.